StreetInsider.com News Articles

Leerink Partners Reiterates Outperform Rating on Cardinal Health (CAH): "company is set up for solid FY2H'26 growth"

Mon, 09 Mar 2026 13:22:06 -0400

Leerink Partners analyst Michael Cherny reiterated an Outperform rating and $275.00 price target on Cardinal Health (NYSE: CAH)

The analyst commented, "We hosted a fireside chat with CFO Aaron Alt, IR Matt Sims, and IR David Frost. Cardinal continues to perform well, benefitting from strong end market demand in addition to robust internal execution. The company is set up for solid FY2H'26 growth, bolstered by strong core trends observed through FY1H'26 thus far. Specialty remains a focus, bolstered by strong volumes in addition to recent M&A in the MSO space. The company is well-positioned for further rounds of IRA-re-contracting. The Other

Form 8-K CARDINAL HEALTH INC For: Mar 02

Thu, 05 Mar 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260305/26114983.html

Form 8-K CARDINAL HEALTH INC For: Mar 02

Thu, 05 Mar 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260305/26114983.html

Form 4 CARDINAL HEALTH INC For: Feb 27 Filed by: Greene Michelle D.

Tue, 03 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260303/26101556.html

Form 4 CARDINAL HEALTH INC For: Feb 27 Filed by: Greene Michelle D.

Tue, 03 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260303/26101556.html

Form 144 CARDINAL HEALTH INC Filed by: Greene Michelle D.

Fri, 27 Feb 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260227/26082698.html

Form 144 CARDINAL HEALTH INC Filed by: Greene Michelle D.

Fri, 27 Feb 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260227/26082698.html

Cardinal Health report highlights cost savings and provider confidence in biosimilars

Tue, 24 Feb 2026 07:00:00 -0400

New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains.

DUBLIN, Ohio, Feb. 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments.

Cardinal Health report highlights cost savings and provider confidence in biosimilars

Tue, 24 Feb 2026 07:00:00 -0400

New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains.

Cardinal Health report highlights cost savings and provider confidence in biosimilars

Tue, 24 Feb 2026 07:00:00 -0400

New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains.

Cardinal Health report highlights cost savings and provider confidence in biosimilars

Tue, 24 Feb 2026 07:00:00 -0400

New analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology leading in adoption and accessibility gains.

Cardinal Health (CAH) PT Raised to $258 at Barclays

Tue, 24 Feb 2026 05:55:51 -0400

Barclays analyst Glen Santangelo raised the price target on Cardinal Health (NYSE: CAH) to $258.00 (from $243.00) while maintaining a Overweight rating.

Form 4 CARDINAL HEALTH INC For: Feb 15 Filed by: Alt Aaron E

Wed, 18 Feb 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260218/26022402.html

Form 4 CARDINAL HEALTH INC For: Feb 15 Filed by: Alt Aaron E

Wed, 18 Feb 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260218/26022402.html

Form 144 CARDINAL HEALTH INC Filed by: Alt Aaron E

Wed, 18 Feb 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260218/26022134.html

Form 144 CARDINAL HEALTH INC Filed by: Alt Aaron E

Wed, 18 Feb 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260218/26022134.html

Cardinal Health (CAH) Declares $0.5107 Quarterly Dividend; 0.9% Yield

Thu, 12 Feb 2026 16:45:04 -0400

Cardinal Health (NYSE: CAH) declared a quarterly dividend of $0.5107 per share, or $2.0428 annualized.

The dividend will be payable on April 15, 2026, to stockholders of record on April 1, 2026, with an ex-dividend date of March 31, 2026.

The annual yield on the dividend is 0.9 percent.

For a dividend history and other dividend-related data on Cardinal Health (CAH) click here.

Cardinal Health Board of Directors Approves Quarterly Dividend

Thu, 12 Feb 2026 16:45:00 -0400

DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026.

Cardinal Health Board of Directors Approves Quarterly Dividend

Thu, 12 Feb 2026 16:45:00 -0400

Cardinal Health Board of Directors Approves Quarterly Dividend

Thu, 12 Feb 2026 16:45:00 -0400

Cardinal Health Board of Directors Approves Quarterly Dividend

Thu, 12 Feb 2026 16:45:00 -0400

Cardinal Health (CAH) PT Raised to $251 at TD Cowen

Wed, 11 Feb 2026 09:16:17 -0400

TD Cowen analyst Charles Rhyee raised the price target on Cardinal Health (NYSE: CAH) to $251.00 (from $233.00) while maintaining a Buy rating.

Form 4 CARDINAL HEALTH INC For: Feb 06 Filed by: Hall Patricia Hemingway

Tue, 10 Feb 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260210/25975801.html

Form 4 CARDINAL HEALTH INC For: Feb 06 Filed by: Hall Patricia Hemingway

Tue, 10 Feb 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260210/25975801.html

Cardinal Health (CAH) PT Raised to $243 at JPMorgan

Tue, 10 Feb 2026 08:40:03 -0400

JPMorgan raised its price target on Cardinal Health (NYSE: CAH) to $243.00 (from $209.00) while maintaining a Neutral rating.